Meet
Mitchell Finkel

Mitchell Finkel supports clients with evidence-based research and analysis that spans healthcare sectors and stakeholders.

With a background in health policy and clinical research, he contributes to the development of client analysis and insights.

Mitchell’s background in health policy, government affairs, and clinical research includes varied research experiences. His clinical research included the administration of a large-scale, cross-sectional survey and assisting in other randomized controlled studies and cohort design studies to assess the effectiveness of the GW Emergency Health Services Department’s interventions. At Todd Strategy, he researched and summarized regulatory and legislative issues affecting the pharmaceutical and bio-tech sectors. Additionally, as a participant in a community hospital rotation program, he gained an understanding of the clinical setting for a variety of medical specialties and the hospital environment, including policies and patient advocacy.

Mitchell has a BS in Public Health from George Washington University.

Authored Content


A new claims-based analysis from Avalere examined vaccine uptake among low-income adolescents enrolled in Medicaid Managed Care and found a 26% decline in routine vaccinations when comparing March–October 2019 to the same period in 2020.

In November 2020, the Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) to COVID-19 monoclonal antibodies for treatment of mild-to-moderate COVID-19 infection.

The majority of state legislatures are currently in session, and many states are taking steps to address prescription drug spending and prices through a range of legislative proposals. While states have historically focused on price transparency, state policymakers are now moving beyond those measures to more directly control prescription drug prices through reference pricing, affordability review boards setting upper payment limits, and other price control mechanisms.

Amid the continuing pandemic and calls for healthcare reform, the new administration seeks to confront the myriad public health issues facing our country today.

On January 21, the Biden administration released its National Strategy for the COVID-19 Response and Pandemic Preparedness. The plan highlights numerous actions that the administration intends to implement as it assumes responsibility in the fight against COVID-19.

Tune into another episode of Get the Facts on COVID-19. In this segment, our vaccines experts discuss state COVID-19 vaccine distribution plans, distribution challenges, and what this space might look like as the vaccines become more widely available.

As the novel coronavirus disease (COVID-19) continues to change daily life, concerns about the impact on global supply chains and possible drug shortages have increased. Additionally, changes to FDA processes may limit its ability to perform essential drug related activities.

New analysis from Avalere finds that states currently covering non-mandatory adult populations who choose to participate in the Healthy Adult Opportunity (HAO) initiative may need to generate up to 8% in Medicaid savings to keep spending below new capped funding levels.